Early Cancer Diagnostics
We invest in blood-based early cancer screening technologies.
We are an appointed accelerator under Enterprise Singapore’s sector-specific accelerator program for MedTech.
Leading the revolution
in Early Cancer Diagnostics
We invest in advanced technologies in blood
drawing and processing methods and
early cancer detection technologies
to compliment our
Group’s primary businesses.
We are focus in delivering
early cancer screening solutions to Asia.
We have our own medical and marketing infrastructure to launch new
innovations successfully into Asia.
MiRXES invests in technologies to provide early screening solutions to Asia.
MiRXES Innovation is also an appointed accelerator under Enterprise Singapore’s Sector Specific Accelerator Programme. It has presence in Singapore, Beijing and Hangzhou.